PROKIDNEY CORP.

ProKidney Corp (Nasdaq: PROK) is a blank check company that completed its initial public offering in 2021, targeting acquisition opportunities in the healthcare and life sciences sector. The company's November 2021 10-Q filing with the SEC reflects its status as a special purpose acquisition vehicle during its search period. ProKidney subsequently completed its de-SPAC merger with ProKidney LLC, a clinical-stage regenerative medicine company developing cell-based therapies aimed at slowing the progression of chronic kidney disease in patients. The combined entity trades under the PROK ticker on Nasdaq as an operating biotech company. Investors and analysts tracking SPAC activity in the healthcare sector can access ProKidney's full filing history, deal timeline, and comparable transactions by signing up at SpacDesk.